PTGX: Protagonist Therapeutics, Inc. Company Value to Net Income
The market capitalization-to-earnings ratio illustrates the asset's valuation trend, where the value 25.30 represents the current figure. The performance of Protagonist Therapeutics (PTGX) is tied to clinical trial timelines and partner payments amid stable cash reserves. Its innovative peptide solution base is being integrated into the portfolios of industry behemoths. Growth is driven by oral drug formulations and the collaboration with J&J for the treatment of psoriasis.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PTGX_-_Protagonist-Therapeutics_-_PE-Multiple "PTGX: Protagonist Therapeutics Business Payback Period 07/04/2022 - 11/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Protagonist Therapeutics Inc (PTGX)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Protagonist Therapeutics|PTGX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Protagonist Corp|PTGX - Company Debts|Debt to Book Value Ratio Protagonist|PTGX - Company Long-Term Debts|Short-Term Debt Protagonist Therapeutics|Critical Liquidity Ratio protagonist-inc.com
- earnings and market multiples details:
PTGX - Company Net Income|Expected Net Income Protagonist Therapeutics|PTGX - Price to Earnings Ratio|Projected Price to Earnings Ratio Protagonist Therapeutics, Inc.|PTGX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Protagonist|PTGX - Operating profit EBITDA|Net earnings per share (EPS TTM) Protagonist Therapeutics|PTGX - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year protagonist-inc.com|PTGX - Earnings per share growth in current year|Expected net earnings per share growth next year Protagonist Therapeutics
- sales volume and revenue indicators:
Comprehensive company analysis:protagonist-inc.com PTGX
Minimizing fundamental risks requires analyzing the market capitalization to net income ratio, which allows for determining the cost of one dollar of earnings and avoiding overpayment during a peak of euphoria. For Protagonist Therapeutics (PTGX), which holds unique patents for peptide drugs, the company's P/E chart clearly demonstrates a fair value corridor, smoothing out the volatility of expectations regarding future stable cash flows.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Immunovant Therapeutics (IMVT)|KNSA - Price to Earnings Ratio|grifols.com (GRFS) - Price to Earnings Ratio|Adaptive Biotechnologies Corporation (ADPT) - Price to Earnings Ratio|Price to Earnings Ratio Celldex Therapeutics Inc|Price to Earnings Ratio AUPH|P/E Multiple BioCryst Corp|Price to Earnings Ratio Vera Therapeutics, Inc. (VERA)|dianthustx.com - Price to Earnings Multiple|P/E Multiple PHVS (Pharvaris)|AbCellera Corp (ABCL) - Market Cap to Earnings|TRML - Price to Earnings Ratio|Market Cap to Net Income PGEN|Pharming Group N.V. (PHAR) - Price to Earnings Ratio|nektar.com - Company Value to Net Income|Price to Earnings Ratio Upstream Bio|Market Cap to Earnings Zenas Bio ZBIO|Price to Earnings Ratio IMNM (Immunome Corp)|Market Price to Net Income Ratio GOSS|P/E Multiple KALV (KalVista Pharmaceuticals)|P/E Multiple septerna.com SEPN|Pieris Pharmaceuticals, Inc. - P/E Multiple|Market Cap to Net Income Ratio Savara Inc (SVRA)|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|Market Cap to Earnings AnaptysBio Inc. (ANAB)|Price to Earnings Ratio Astria Therapeutics|Price to Earnings Multiple ENGN (engene.com)|P/E Multiple RAPT|Business Payback Period aerovatetx.com|Price to Earnings Ratio Aclaris ACRS|Business Payback Period Kyverna Therapeutics, Inc (KYTX)|TLSA: Price to Earnings Ratio|cabalettabio.com - Market Price to Net Income Ratio|VTYX (Ventyx Biosciences, Inc.) - Price to Earnings Ratio|Theratechnologies, Inc. - Company Value to Net Income|Price to Earnings Ratio AVTX|ELDN (Eledon Pharmaceuticals, Inc) - Market Price to Net Income Ratio|P/E Multiple AGEN|CLYM (climbbio.com) - Company Value to Net Income|P/E Multiple ZURA (Zura Bio)|aTyr Pharma Inc (ATYR) - Market Cap to Earnings|ADAG - Price to Earnings Ratio|Company Value to Net Income IMA (ImageneBio Inc)|STTK: P/E Multiple|Equillium (EQ) - P/E Multiple|Price to Earnings Ratio Connect Biopharma Holdings|Immunic Inc - Market Cap to Net Income|P/E Multiple ATRA|IFRX - Market Cap to Earnings|X4 Pharmaceuticals - Price to Earnings Ratio|P/E Multiple Adicet Bio Inc. ACET|CELU: Price to Earnings Ratio|INmune Bio Inc - Market Price to Net Income Ratio|BRNS: P/E Multiple|KZR - Business Payback Period|SABS (SAB Biotherapeutics) - P/E Multiple|Price to Earnings Ratio akaritx.com (AKTX)|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|Business Payback Period q32bio.com|Price to Earnings Ratio GeoVax Labs Inc GOVX|EDSA (Edesa Biotech Corp) - Market Cap to Net Income|IBIO: Price to Earnings Ratio|Carisma Therapeutics - Market Price to Net Income Ratio|XTLB: P/E Multiple|Market Cap to Net Income Ratio Bolt Biotherapeutics, Inc. BOLT|Price to Earnings Ratio HCWB|Price to Earnings Multiple APVO (Aptevo)|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|ADTX: Market Cap to Net Income|P/E Multiple GRI (GRI Bio)|Company Value to Net Income XRTX|ReShape Lifesciences - P/E Multiple|REVB - P/E Multiple|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|scinai.com - Company Value to Net Income|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Ratio Affimed Therapeutics (AFMD)|P/E Multiple ALLK|P/E Multiple hookipapharma.com (HOOK)|IGM Biosciences - Price to Earnings Ratio|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|Business Payback Period TC BioPharm (Holdings) Plc TCBP|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
